Primary tumor cells from cancer patients “decorated” with a novel form of CD80 protein effectively induce autologous T-cell responses ex-vivo

Abstract

2580 Background: The genetic modification of tumor cells is an elaborate process and has several limitations for effective use as cancer immunotherapy in clinical settings. We have recently developed a novel technology, ProtExa, that allows for rapid, efficient, and durable display of exogenous proteins on the cell surface. This technology involves generation of chimeric molecules composed of immunological proteins of interest and core streptavidin, biotinylation of biological surfaces, and decoration with chimeric proteins. In a mouse B lymphoma model, vaccination with tumor cells decorated with a chimeric costimulatory protein (CD80-SA) containing the extracellular portion of human CD80 and core streptavidin was effective in preventing tumor growth in 100% of animals. In this study, we tested whether primary tumor cells resected from cancer patients and decorated with CD80-SA can induce autologous proliferative and cytotoxic T-cell responses ex vivo. Methods: Primary tumor cells and blood samples were c...